Targeting metabotropic glutamate receptors in the treatment of primary brain tumors

Luisa Iacovelli, Rosamaria Orlando, Alessandro Rossi, Paola Spinsanti, Daniela Melchiorri, Ferdinando Nicoletti

Research output: Contribution to journalReview article

Abstract

In spite of the recent advancement in the molecular characterization of malignant gliomas and medulloblastomas, the treatment of primary brain tumors remains suboptimal. The use of small molecule inhibitors of intracellular signaling pathways, inhibitors of angiogenesis, and immunotherapic agents is limited by systemic adverse effects, limited brain penetration, and, in some cases, lack of efficacy. Thus, adjuvant chemo-therapy and radiotherapy still remain the gold standard in the treatment of grade-IV astrocytoma (glioblastoma multiforme) and medulloblastoma. We review evidence that supports the development of mGlu3 receptor antagonists as add-on drugs in the treatment of malignant gliomas. These drugs appear to display pleiotropic effect on tumor cells, affecting proliferation, differentiation, and response to chemotherapy. mGlu1 and mGlu4 receptors could also be targeted by potential anticancer agents in the treatment of malignant gliomas and medulloblastoma, but extensive research is required for target validation.

Original languageEnglish
Pages (from-to)59-64
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume38
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Metabotropic Glutamate Receptors
Brain Neoplasms
Medulloblastoma
Glioma
Glioblastoma
Therapeutics
Angiogenesis Inhibitors
Pharmaceutical Preparations
Antineoplastic Agents
Radiotherapy
Cell Proliferation
Drug Therapy
Brain
Research
Neoplasms

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Targeting metabotropic glutamate receptors in the treatment of primary brain tumors. / Iacovelli, Luisa; Orlando, Rosamaria; Rossi, Alessandro; Spinsanti, Paola; Melchiorri, Daniela; Nicoletti, Ferdinando.

In: Current Opinion in Pharmacology, Vol. 38, 01.02.2018, p. 59-64.

Research output: Contribution to journalReview article

Iacovelli, Luisa ; Orlando, Rosamaria ; Rossi, Alessandro ; Spinsanti, Paola ; Melchiorri, Daniela ; Nicoletti, Ferdinando. / Targeting metabotropic glutamate receptors in the treatment of primary brain tumors. In: Current Opinion in Pharmacology. 2018 ; Vol. 38. pp. 59-64.
@article{727bbbc2150942ba9e6e352718d80d21,
title = "Targeting metabotropic glutamate receptors in the treatment of primary brain tumors",
abstract = "In spite of the recent advancement in the molecular characterization of malignant gliomas and medulloblastomas, the treatment of primary brain tumors remains suboptimal. The use of small molecule inhibitors of intracellular signaling pathways, inhibitors of angiogenesis, and immunotherapic agents is limited by systemic adverse effects, limited brain penetration, and, in some cases, lack of efficacy. Thus, adjuvant chemo-therapy and radiotherapy still remain the gold standard in the treatment of grade-IV astrocytoma (glioblastoma multiforme) and medulloblastoma. We review evidence that supports the development of mGlu3 receptor antagonists as add-on drugs in the treatment of malignant gliomas. These drugs appear to display pleiotropic effect on tumor cells, affecting proliferation, differentiation, and response to chemotherapy. mGlu1 and mGlu4 receptors could also be targeted by potential anticancer agents in the treatment of malignant gliomas and medulloblastoma, but extensive research is required for target validation.",
author = "Luisa Iacovelli and Rosamaria Orlando and Alessandro Rossi and Paola Spinsanti and Daniela Melchiorri and Ferdinando Nicoletti",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.coph.2018.02.005",
language = "English",
volume = "38",
pages = "59--64",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Targeting metabotropic glutamate receptors in the treatment of primary brain tumors

AU - Iacovelli, Luisa

AU - Orlando, Rosamaria

AU - Rossi, Alessandro

AU - Spinsanti, Paola

AU - Melchiorri, Daniela

AU - Nicoletti, Ferdinando

PY - 2018/2/1

Y1 - 2018/2/1

N2 - In spite of the recent advancement in the molecular characterization of malignant gliomas and medulloblastomas, the treatment of primary brain tumors remains suboptimal. The use of small molecule inhibitors of intracellular signaling pathways, inhibitors of angiogenesis, and immunotherapic agents is limited by systemic adverse effects, limited brain penetration, and, in some cases, lack of efficacy. Thus, adjuvant chemo-therapy and radiotherapy still remain the gold standard in the treatment of grade-IV astrocytoma (glioblastoma multiforme) and medulloblastoma. We review evidence that supports the development of mGlu3 receptor antagonists as add-on drugs in the treatment of malignant gliomas. These drugs appear to display pleiotropic effect on tumor cells, affecting proliferation, differentiation, and response to chemotherapy. mGlu1 and mGlu4 receptors could also be targeted by potential anticancer agents in the treatment of malignant gliomas and medulloblastoma, but extensive research is required for target validation.

AB - In spite of the recent advancement in the molecular characterization of malignant gliomas and medulloblastomas, the treatment of primary brain tumors remains suboptimal. The use of small molecule inhibitors of intracellular signaling pathways, inhibitors of angiogenesis, and immunotherapic agents is limited by systemic adverse effects, limited brain penetration, and, in some cases, lack of efficacy. Thus, adjuvant chemo-therapy and radiotherapy still remain the gold standard in the treatment of grade-IV astrocytoma (glioblastoma multiforme) and medulloblastoma. We review evidence that supports the development of mGlu3 receptor antagonists as add-on drugs in the treatment of malignant gliomas. These drugs appear to display pleiotropic effect on tumor cells, affecting proliferation, differentiation, and response to chemotherapy. mGlu1 and mGlu4 receptors could also be targeted by potential anticancer agents in the treatment of malignant gliomas and medulloblastoma, but extensive research is required for target validation.

UR - http://www.scopus.com/inward/record.url?scp=85043243893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043243893&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2018.02.005

DO - 10.1016/j.coph.2018.02.005

M3 - Review article

VL - 38

SP - 59

EP - 64

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -